Juan Carlos Garnica-Cuellar, Enrique Morales-Villegas, Carmen Alicia López-Forero, Bárbara Monroy-Cruz, Bhrugu Pariti, Swati Deshwal, Manisha Sekharan, Mariana Osorio-Hernández, Ida Caterina García-Appendini
OBJECTIVES: Achieving glycemic control in patients with type 2 diabetes is important as it reduces the risk of complications and their related clinical and economic burden. Yet therapeutic inertia due to the fear of hypoglycemia, complex treatment regimens, weight gain, and therapy costs, among others, limits achieving glycemic control. This analysis aims to assess the short-term cost of control (cost per patient achieving treatment goals) with insulin degludec/liraglutide (IDegLira) versus other forms of basal insulin intensification (insulin glargine titration, basal-bolus therapy, and the combination of insulin glargine and lixisenatide: IGlarLixi) in type 2 diabetes patients not controlled with basal insulin in the Mexican private setting...
July 15, 2023: PharmacoEconomics Open